Shares of Connect Biopharma Holdings Limited (NASDAQ:CNTB – Get Rating) dropped 2% during mid-day trading on Tuesday . The company traded as low as $0.80 and last traded at $0.80. Approximately 117,506 shares changed hands during trading, a decline of 60% from the average daily volume of 291,173 shares. The stock had previously closed at $0.82.
Wall Street Analysts Forecast Growth
CNTB has been the topic of a number of research reports. SVB Leerink initiated coverage on shares of Connect Biopharma in a research report on Friday, April 1st. They set a “buy” rating and a $22.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Connect Biopharma in a research report on Thursday, June 2nd. Finally, Piper Sandler lowered shares of Connect Biopharma from an “overweight” rating to a “neutral” rating in a research report on Thursday, May 5th.
Connect Biopharma Stock Down 1.2 %
The company’s fifty day simple moving average is $0.85 and its 200-day simple moving average is $2.52.
Institutional Investors Weigh In On Connect Biopharma
Connect Biopharma Company Profile
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
- Get a free copy of the StockNews.com research report on Connect Biopharma (CNTB)
- Ford Stock Rallies As EV Strategy Takes Center Stage
- Should High Yield Altria Be In Your Portfolio?
- Is Keurig-Dr. Pepper A Value Worth Buying?
- C3.AI Stock is a Bargain Enterprise Artificial Intelligence Game Changer
- Did The FOMC Put A Bottom In The S&P 500?
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.